Early response and safety of lenvatinib for patients with advanced hepatocellular carcinoma in a real‐world setting

Early response and safety of lenvatinib for patients with advanced hepatocellular carcinoma in a real‐world setting

Lenvatinib has been recently approved as a first-line systematic therapy for patients with advanced hepatocellular carcinoma (HCC) based on the results of the phase 3 clinical trial REFLECT. This trial excluded patients with a history of systemic chemotherapy, bile duct invasion, and Child-Pugh grad...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Takuya Sho, Goki Suda, Koji Ogawa, Megumi Kimura, Tomoe Shimazaki, Osamu Maehara, Taku Shigesawa, Kazuharu Suzuki, Akihisa Nakamura, Masatsugu Ohara, Machiko Umemura, Naoki Kawagishi, Mitsuteru Natsuizaka, Masato Nakai, Kenichi Morikawa, Ken Furuya, Masaru Baba, Yoshiya Yamamoto, Tomoe Kobayashi, Takashi Meguro, Akiyoshi Saga, Takuto Miyagishima, Hideki Yokoo, Toshiya Kamiyama, Akinobu Taketomi, Naoya Sakamoto
Format: Artigo
Jezik:angleščina
Izdano: 2019
Online dostop:https://doi.org/10.1002/jgh3.12209
https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/jgh3.12209
Oznake: Označite
Brez oznak, prvi označite!

Internet

https://doi.org/10.1002/jgh3.12209
https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/jgh3.12209

Podobne knjige/članki